TransMedics: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, TransMedics (TMDX +6.29%) announced full-year 2026 revenue guidance of $764 million to $774 million. The company is advancing several clinical initiatives to expand the use of its medical devices across donor organs. Three things management said stand out for long-term investors.

1. Case Volume Growth Drives Highest Quarterly Revenue in Company History

Third-quarter revenue reached $203 million, up 41% year over year, despite the typical summer lull in donor activity. Increasing customer adoption of organ preservation technology helped offset a 6% drop in overall U.S. donor organ availability during the quarter.

The third quarter of 2026 was the strongest in TransMedics’ history for both revenue and case volume.
— Waleed Hassanein, President and Chief Executive Officer

2. Expanded Clinical Protocols Open Thousands of Additional Heart and Lung Procedures

Management is expanding enrollment in its ENHANCE heart and DENOVO lung clinical programs, which use warm perfusion and cold storage options to broaden patient eligibility. These initiatives aim to capture thousands of annual procedures that currently use no machine preservation technology.

Taken together, ENHANCE Heart and DENOVO Lung give us access to conservatively estimated 2,000 to 5,000 incremental U.S. heart and lung cases annually, materially expanding our U.S. addressable market.
— Waleed Hassanein, President and Chief Executive Officer

3. Kidney Preservation System Targets the Largest Addressable Transplant Market

TransMedics is developing a portable kidney system to address organs currently discarded due to prolonged ischemia or damage from lack of blood flow during transport. First human clinical testing remains scheduled for the second half of 2027.

In the U.S., approximately 21,000 diseased donor kidneys are transplanted each year and approximately 9,000 more go unused, in part due to prolonged ischemic time.
— Waleed Hassanein, President and Chief Executive Officer

Looking Ahead

Case volumes are reaching all-time highs as hospital adoption expands. TransMedics relies on its owned aviation fleet and donor screening services while management tracks European expansion and clinical trial progress.

We enter 2027 with strong momentum and a robust set of growth catalysts.
— Waleed Hassanein, President and Chief Executive Officer

Manufacturing efficiencies and next-generation organ preservation systems are expected to drive operating leverage as new clinical indications scale.

We are building the global platform to transform organ transplantation, and we strongly believe our best years are still ahead.
— Waleed Hassanein, President and Chief Executive Officer